CGRP monoclonal antibodies: others
Evidence-based neurology checklist on cgrp monoclonal antibodies: others: Fremanezumab The dose for episodic migraine is 225mg monthly or 675mg quarterly SC The quarterly dose for chronic migraine is 675mg SC The monthly dose for chronic migraine is 675mg loading dose and 225mg monthly SC…
Fremanezumab
- The dose for episodic migraine is 225mg monthly or 675mg quarterly SC
- The quarterly dose for chronic migraine is 675mg SC
- The monthly dose for chronic migraine is 675mg loading dose and 225mg monthly SC
Galcanezumab
Eptinezumab
Acronym
References
- Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015; 14:1081-1090.
- Melo-Carrillo A, Noseda R, Nir R, Schain A, Stratton J, Strassman AM, Burstein R. Selective inhibition of trigeminovascular neurons by fremanezumab-a humanized monoclonal anti-CGRP antibody. J Neurosci 2017; pii: 0576-17 (Epub ahead of print).
- Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. NEJM 2017; 377:2113-2122.
- Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 2018; 319:1999-2008.
- Halker Singh RB, Aycardi E, Bigal ME, Loupe PS, McDonald M, Dodick DW. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials. Cephalalgia 2018; doi: 10.1177/0333102418772585 (Epub ahead of print).
- And 15 more. Subscribe to see the full list
